Actively Recruiting
Effectiveness of Platform-Based Lateralization Therapy in Reducing Interface Pressure Between The Patient And The Support Surface
Led by University of Sao Paulo General Hospital · Updated on 2025-06-22
25
Participants Needed
1
Research Sites
173 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Pressure injury (PI) is characterized as damage to the skin and/or underlying tissues resulting from sustained pressure or a combination of pressure and shear forces between the patient and the support surface. Prolonged pressure is a well-established risk factor in the development of PIs. Frequent repositioning and routine patient care have been recognized for decades as integral components of PI prevention and treatment protocols. The duration of interface pressure is as critical as its magnitude. When interface pressure exceeds the mean capillary blood pressure, blood flow can be compromised, leading to ischemia in affected areas, which may progress to necrosis if sustained over time. Furthermore, it is widely accepted in the literature that tissue becomes at risk when interface pressure exceeds 30 to 32 mmHg. In this context, continuous lateral rotation therapy (CLRT) offers a potential alternative for managing critically ill patients. CLRT involves continuous mechanical rotation of the patient in the lateral plane. However, its effects on skin integrity remain poorly understood. Despite the rationale behind and widespread recommendation of repositioning, the lack of robust evaluations on how repositioning impacts interface pressure creates uncertainty, underscoring the need for high-quality trials to assess different strategies for implementation. Although lateralization is a pragmatic strategy for preventing pressure injuries, its use in critically ill patients requires an integrated assessment of respiratory, hemodynamic, and gastroesophageal effects. Therefore, this study proposes an innovative approach by evaluating, for the first time, the effectiveness of automated postural change with simultaneous monitoring of tissue integrity, pulmonary function, cardiovascular stability, and gastroesophageal protection. The aim is to optimize pressure injury prevention, improve pulmonary mechanics, ensure hemodynamic stability, and preserve gastroesophageal safety in critically ill patients.
CONDITIONS
Official Title
Effectiveness of Platform-Based Lateralization Therapy in Reducing Interface Pressure Between The Patient And The Support Surface
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult and elderly patients, aged 18 years or older
- Patients under controlled or assisted mechanical ventilation, not yet eligible for weaning
You will not qualify if you...
- Requirement of norepinephrine greater than 0.3 mcg/kg/min or mean arterial pressure below 60 mmHg despite vasopressor use
- Cardiac arrhythmias or bleeding causing hemodynamic instability
- Neurological diseases or symptoms
- Spinal cord injury such as paraplegia
- Cardiac pacemaker dependence
- Contraindications to hypercapnia like intracranial hypertension or acute coronary syndrome
- Air leakage from chest drains, pneumothorax, or undrained subcutaneous emphysema
- Presence of pre-existing pressure injuries on sacral, occipital, scapular, or calcaneal areas at admission
- Medical refusal to include the patient in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade São Paulo
São Paulo, São Paulo, Brazil, 05403-900
Actively Recruiting
Research Team
M
Marcelo BP Amato, MD PhD
CONTACT
A
Anne C Almeida de Sousa, PT
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here